Carlo Genova
A5086247944- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Ferroptosis and cancer prognosis
- RNA modifications and cancer
- Peptidase Inhibition and Analysis
- Immunotherapy and Immune Responses
- Cancer Cells and Metastasis
- Occupational and environmental lung diseases
- Neuroendocrine Tumor Research Advances
- CAR-T cell therapy research
- Medical Imaging and Pathology Studies
- COVID-19 and healthcare impacts
- Inflammatory Biomarkers in Disease Prognosis
- Molecular Biology Techniques and Applications
- Pancreatic and Hepatic Oncology Research
- Extracellular vesicles in disease
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Medical Imaging Techniques and Applications
- Immune Cell Function and Interaction
- HER2/EGFR in Cancer Research
Ospedale Policlinico San Martino
2016-2025
University of Genoa
2017-2025
Italian Oncology Group of Clinical Research
2025
Associazione Italiana Di Oncologia Medica
2021-2022
Istituti di Ricovero e Cura a Carattere Scientifico
2013-2022
University of Modena and Reggio Emilia
2022
University of Turin
2022
IRCCS Eugenio Medea
2020
Alleanza Contro il Cancro
2016-2020
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2018-2019
CEA, CYFRA21-1 and NSE are tumor markers used for monitoring the response to chemotherapy in advanced adenocarcinoma, squamous cell carcinoma small-cell lung cancer, respectively. Their role cancer immunotherapy needs be elucidated.Patients with non-small (NSCLC) were treated nivolumab 3 mg/kg every 2 weeks within Italian Nivolumab Expanded Access Program. Blood samples collected at baseline, each cycle up 5 then two cycles until patient's withdrawn from study. All patients underwent a...
Geriatric (aged ≥80 years) patients are historically underrepresented in cancer clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) geriatric patients. These agents associated with immune-related adverse events (irAEs), which may be particularly morbidity this population.To provide insight into outcomes and safety ICIs among cancer.A Multicenter, international retrospective study 928 different tumors treated single-agent between 2010 to 2019 from 18...
Background Some concomitant medications including antibiotics (ATB) have been reproducibly associated with worse survival following immune checkpoint inhibitors (ICIs) in unselected patients non-small cell lung cancer (NSCLC) (according to programmed death-ligand 1 (PD-L1) expression and treatment line). Whether such relationship is causative or associative matter of debate. Methods We present the outcomes analysis according baseline (prior ICI initiation) putative immune-modulatory effects...
Radiomics is defined as the use of automated or semi-automated post-processing and analysis multiple features derived from imaging exams. Extracted might generate models able to predict molecular profile solid tumors. The aim this study was develop a predictive algorithm define mutational status EGFR in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC). CT scans 109 NSCLC (21 EGFR-mutant 88 EGFR-wild type) underwent radiomics machine learning model recognize EGFR-WT...
Background The association between obesity and outcomes in patients receiving programmed death-1/programmed death ligand-1 (PD-L1) checkpoint inhibitors has already been confirmed pre-treated non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 tumor expression. Methods We present the analysis according to baseline body mass index (BMI) BMI variation a large cohort metastatic NSCLC with expression ≥50%, first line pembrolizumab. also evaluated control treated platinum-based...
Immune checkpoint blockade represents a major breakthrough in advanced non-small cell lung cancer (NSCLC) therapy. However, success is limited to subset of patients and there critical need identify robust biomarkers associated with clinical response. In this study, we assessed whether pre-existing immunological characteristics, as well immune parameters measured during treatment, might provide such guidance. We studied blood samples collected at baseline treatment cohort NSCLC (n = 74)...
COVID-19 has disrupted the global health care system since March 2020. Lung cancer (LC) patients (pts) represent a vulnerable population highly affected by pandemic. This multicenter Italian study aimed to evaluate whether outbreak had an impact on access diagnosis and treatment of LC pts compared with pre-pandemic time.Consecutive newly diagnosed referred 25 Oncology Departments between December 2020 were included. Access rate temporal intervals date symptoms onset diagnostic therapeutic...
Compared with people living without HIV (PWOH), (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use ICIs in PWH cancer.
Abstract Background Rare cases of severe myocarditis are reported during treatment with nivolumab. Troponin, a biomarker cardiac damage, is key component the diagnostic workup many disorders, including myocarditis. This study investigates role troponin to assess involvement nivolumab therapy for non-small cell lung cancer (NSCLC). Materials and Methods We evaluated 59 NSCLC patients, analyzing serum samples collected within translational research study. Troponin above upper normal limit...
To stratify the prognosis of patients with programmed cell death-ligand 1 (PD-L1) ≥ 50% advanced non-small-cell lung cancer (aNSCLC) treated first-line immunotherapy.Baseline clinical prognostic factors, neutrophil-to-lymphocyte ratio (NLR), PD-L1 tumour expression level, lactate dehydrogenase (LDH) and their combination were investigated by a retrospective analysis 784 divided between statistically powered training (n = 201) validation 583) cohorts. Cut-offs explored receiver operating...